These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16505512)

  • 1. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
    Ibsen H; Olsen MH; Wachtell K; Borch-Johnsen K; Lindholm LH; Mogensen CE; Dahlöf B; Snapinn SM; Wan Y; Lyle PA
    Diabetes Care; 2006 Mar; 29(3):595-600. PubMed ID: 16505512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
    Ibsen H; Olsen MH; Wachtell K; Borch-Johnsen K; Lindholm LH; Mogensen CE; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Julius S; Kjeldsen SE; Lederballe-Pedersen O; Nieminen MS; Omvik P; Oparil S; Wan Y
    Hypertension; 2005 Feb; 45(2):198-202. PubMed ID: 15655123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
    Ibsen H; Wachtell K; Olsen MH; Borch-Johnsen K; Lindholm LH; Mogensen CE; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Julius S; Kjeldsen SE; Lederballe-Pedersen O; Nieminen MS; Omvik P; Oparil S; Wan Y;
    J Hypertens; 2004 Sep; 22(9):1805-11. PubMed ID: 15311110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
    Olsen MH; Wachtell K; Ibsen H; Lindholm LH; Dahlöf B; Devereux RB; Kjeldsen SE; Oikarinen L; Okin PM;
    J Hypertens; 2006 Apr; 24(4):775-81. PubMed ID: 16531808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
    Olsen MH; Wachtell K; Bella JN; Palmieri V; Gerdts E; Smith G; Nieminen MS; Dahlöf B; Ibsen H; Devereux RB
    Am J Hypertens; 2005 Nov; 18(11):1430-6. PubMed ID: 16280277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
    Fyhrquist F; Dahlöf B; Devereux RB; Kjeldsen SE; Julius S; Beevers G; de Faire U; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Hille DA; Lyle PA; Edelman JM; Snapinn SM; Wedel H;
    Hypertension; 2005 Apr; 45(4):580-5. PubMed ID: 15790960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Ruwald AC; Westergaard B; Sehestedt T; Kjeldsen SE; Lindholm LH; Wachtell K; Devereux RB; Ibsen H; Nieminen MS; Dahlöf B; Olsen MH
    J Hypertens; 2012 Jun; 30(6):1252-9. PubMed ID: 22499288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
    Fossum E; Gleim GW; Kjeldsen SE; Kizer JR; Julius S; Devereux RB; Brady WE; Hille DA; Lyle PA; Dahlöf B
    J Intern Med; 2007 Oct; 262(4):439-48. PubMed ID: 17875180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
    Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
    Olsen MH; Wachtell K; Nielsen OW; Hall C; Wergeland R; Ibsen H; Kjeldsen SE; Devereux RB; Dahlöf B; Hildebrandt PR
    J Hypertens; 2006 Aug; 24(8):1531-9. PubMed ID: 16877955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
    Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; Aurup P; Edelman J; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
    JAMA; 2002 Sep; 288(12):1491-8. PubMed ID: 12243636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention For Endpoint reduction.
    Olsen MH; Wachtell K; Borch-Johnsen K; Okin PM; Kjeldsen SE; Dahlöf B; Devereux RB; Ibsen H
    J Hum Hypertens; 2002 Aug; 16(8):591-5. PubMed ID: 12149666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
    Søraas CL; Wachtell K; Okin PM; Dahlöf B; Devereux RB; Tønnessen T; Kjeldsen SE; Olsen MH
    Blood Press; 2010 Jun; 19(3):145-51. PubMed ID: 20429689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
    Kjeldsen SE; Devereux RB; Hille DA; Lyle PA; Dahlöf B; Julius S; Edelman JM; Snapinn SM; de Faire U; Fyhrquist F; Ibsen H; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Blood Press; 2009; 18(6):348-61. PubMed ID: 20001655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study.
    Devereux RB; Bang CN; Roman MJ; Palmieri V; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Wachtell K; Hille DA; Dahlöf B
    Hypertension; 2015 Nov; 66(5):945-53. PubMed ID: 26418019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
    Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
    Gerdts E; Wachtell K; Omvik P; Otterstad JE; Oikarinen L; Boman K; Dahlöf B; Devereux RB
    Hypertension; 2007 Feb; 49(2):311-6. PubMed ID: 17178978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
    Ibsen H; Lindholm LH; Pedersen OL; Dahlöf B; Kjeldsen S
    Ugeskr Laeger; 2003 Jan; 165(5):459-62. PubMed ID: 12599844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Lindholm LH; Dahlöf B;
    Hypertension; 2007 Nov; 50(5):984-90. PubMed ID: 17893425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.